FirstWord's Duncan Emerton (Senior Director, Syndicated Insights & Analysis) and Simon King (Executive Editor, FirstWord Pharma PLUS) discuss the implications of new rheumatoid arthritis guidance issued by the UK's NICE - in particular its impact on the biosimilar infliximab market.
To read more The First Take articles, click here.
